Jordan, Lebanon join GSK’s bribery investigations list
British drugmaker GlaxoSmithKline (GSK) has announced Jordan and Lebanon have been added to a growing list of countries, where it is investigating allegations of bribery, The Telegraph has reported. The company said it is investigating allegations “regarding the activity of a small number of individuals” in its operations in Jordan and Lebanon, where it employs a combined 140 staff. The company has admitted that its own investigation into the allegations unearthed evidence of wrongdoing by a handful of sales staff, but maintains they worked outside GSK’s control systems. Last year, GSK became the first drugmaker to end payments to doctors to promote its drugs and scrap individual sales targets for staff in an effort to tackle breaches of its code.